Home>
Stocks>
Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd (SPARC)

₹237.35▲2.17%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Technicals

News and Events

Sun Pharma Advanced Research Company Ltd share Performance

₹220.7
₹243.8
₹237.35
7.01%
Low
Day's Volatility:9.73%
High
2.72%
₹178.8
₹472.8
₹237.35
24.67%
Low
52 Weeks Volatility:123.87%
High
99.20%

Returns %
1 Month Return	-39.54 %
3 Month Return	-36.15 %
1 Year Return	18.88 %

Market Stats
Previous Close	₹232.30
Open	₹220.70
Volume	1.22Cr
Upper Circuit	-
Lower Circuit	-
Market Cap	₹7,538.64Cr

Company Information

Sun Pharma Advanced Research Company Ltd (“SPARC”) is a clinical stage biopharmaceutical company focused on innovation and new product development for global markets. Established in 2006, it is engaged in the creation of new drugs and delivery systems, undertaking projects in research and technology for new chemical entities (“NCEs”) and novel drug delivery systems (“NDDS”). SPARC operates in global markets including the US, India and China. It has successfully received approvals from the US FDA for various drugs such as ELEPSIA XR Levetiracetam extended-release tablets 1000 mg and 1500 mg, XELPROS Latanoprost BAKfree eyedrops and for XELPROS latanoprost ophthalmic emulsion 0.005 which was inlicensed from Sun Pharma in 2015. In 2021, it commenced the commercialization of ElepsiaTM XR to Visiox Pharma, with eligible milestone payments and royalties and acquired exclusive rights for antibody against a unique oncology target from Biomodifying. SPARC is focused on advancement of clinical trials with vodobatinib being granted orphan drug designation for the treatment of CML and it has completed phase I study of SCD044.

Share Price: ₹237.35 per share as on 02 May, 2024 04:01 PM
Market Capitalisation: ₹7,538.64Cr as of today
Revenue: ₹13.86Cr as on December 2023 (Q4 23)
Net Profit: ₹-99.65Cr as on December 2023 (Q4 23)
Listing date: 18 Jul, 2007
Chairperson Name: Dilip S Shanghvi

Organisation	Sun Pharma Advanced Research Company Ltd
Headquarters	Mumbai
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Sun Pharma Advanced Research Company Ltd

SPARC Stock Gains After Losing Streak - 02 May, 2024
Shares of Sun Pharma Advanced Research Company (SPARC) gained 4% after a 14-day losing streak, during which the stock declined by 49%. SPARC is not raising any further equity and plans to cut costs. Currently down 21% in 2024, the stock has erased all year-to-date gains.
Sun Pharma Advanced Research Company's Stock Plummets on Trial Closure - 26 Apr, 2024
Shares of Sun Pharma Advanced Research Company have fallen 40% in the last 10 trading days after the decision to close the phase 2 study of Vodobatinib for Parkinson's. The stock hit a lower circuit and is locked at ₹258.25, with almost 48,69,755 sell quantity pending on NSE.
SPARC Shares Locked in Lower Circuit for 10th Straight Day - 25 Apr, 2024
Shares of Sun Pharma Advanced Research Company (SPARC) Ltd. have fallen below all key moving averages and are now down 12% for the year. SPARC's stock price decline is due to poor results from its flagship asset Vodobatinib in patients with Early Parkinsons disease.
SPARC Stock Continues to Fall After Negative Study Results - 18 Apr, 2024
Shares of Sun Pharma Advanced Research Company (SPARC) Ltd. have fallen by 23% over the past six trading sessions following negative results from a study on its flagship asset, Vodabatinib, which was being tested as a potential first-in-class therapeutic agent to treat early stage Parkinson's.
Sun Pharma Advanced Research Company Ltd down 5% - 12 Apr, 2024
Sun Pharma Advanced Research Company Ltd lost 5% to trade at Rs 409.55, while the S&P BSE Healthcare index is down 0.63%. The stock has added 14.83% over last one month compared to a 5.15% gain in the S&P BSE Healthcare index and a 2.83% rise in the SENSEX.
SPARC Abandons Study on Vodobatinib for Parkinson's Disease - 10 Apr, 2024
Shares of Sun Pharma Advanced Research Company (SPARC) fell 5% after the company announced that it was abandoning Phase 2 study on Vodobatinib for Parkinsons. The trial failed to demonstrate superiority of Vodobatinib compared to placebo. SPARC plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months.
Sun Pharma Advanced Research Stock Resumes Uptrend - 08 Apr, 2024
After trading sideways, Sun Pharma Advanced Research's stock gained nearly 18% last week, indicating a resumption of the uptrend. Analysts expect the price to rally to ₹500 in the short term and recommend buying at ₹433 with stop-loss at ₹375.

Fundamentals of Sun Pharma Advanced Research Company Ltd

Insights on Sun Pharma Advanced Research Company Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 30.21% to 30.28% in Mar 2024 quarter
POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 0.24% to 0.25% in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 54.4% return, outperforming this stock by 35.5%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.9% return, outperforming this stock by 94.8%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 65.67% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 3.30% to 3.23% in Mar 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 7 days, SPARC stock has moved down by -14.3%

Mutual Fund Holdings

Funds	Holdings
Quant ELSS Tax Saver Growth Option Direct Plan	0.26%
ITI Pharma and Healthcare Fund Direct Growth	1.35%
Nippon India Nifty Smallcap 250 Index Fund Dir Gr	0.19%
SBI Nifty Smallcap 250 Index Fund Direct Growth	0.19%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct Growth	0.19%